Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue
+10.2%
EPS
+22.2%
Free cash flow
−4.83%

Quarter to September 2026, against a year earlier

69.55 0.84 +1.22%
Market cap
$16.8B
P/E
19.9×
Fwd P/E
20.2×
Dividend yield
—
F-score
7/9
Altman Z
12.68
Beneish M
−2.61
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
7 7 7 7

+8 more TTM periods

ROE
44.32% 44.39% 40.99% 35.53%
ROA
33.17% 33.28% 30.69% 27.02%
ROIC
66.59% 60.45% 50.53% 49.46%
Return on Tangible Assets
88.78% 87.68% 89.31% 68.85%
Average Days of Receivables
48.02 48.28 50.54 45.14
Free Cash Flow per Share
4.64 4.62 3.50 3.11
Free Cash Flow
1,144.49 1,158.19 905.17 844.34
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026